Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: Impact on outcome reporting

Heart

Volumn 98, Issue 19, 2012, Pages 1424-1430

  Vranckx, Pascal ^a,b   Farooq, Vasim ^c   Garg, Scot ^c   Van Es, Gerrit Anne ^b   Silber, Sigmund ^a   Windecker, Stephan ^d   Stone, Gregg W ^e   Serruys, Patrick W ^c  

^a Hartcentrum Hasselt ^*  (Germany)

^b CARDIALYSIS   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BERN   (Switzerland)

^e New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; TROPONIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE NECROSIS; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERI PROCEDURAL HEART INFARCTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TROPONIN T;

EID: 84866057851     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302267     Document Type: Article

References (29)

1. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med 2011;364:453-64.
2. Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented? Heart 2010;96:736-40.
3. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005;26:2493-519. (Pubitemid 41679359)
4. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356-75. (Pubitemid 46648624)
5. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:123-35.
6. Silber S, Windecker S, Vranckx P, et al RESOLUTE All Comers Investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-7.
7. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
8. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.
9. de Boer SP, Lenzen MJ, Oemrawsingh RM, et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. Eur Heart J 2011;32:2161-7.
10. Thygesen K, Alpert JS, White HD, et al Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38. (Pubitemid 47616190)
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51. (Pubitemid 46685903)
12. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. EuroIntervention 2010;5:871-4.
13. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9. (Pubitemid 46376802)
14. Agewall S, Giannitsis E, Jernberg T, et al. Troponin elevation in coronary vs. noncoronary disease. Eur Heart J 2011;32:404-11.
15. Westgard J, Klee G. Quality management. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics . 4th edn. St Louis, MO: Elsevier Saunders, 2006:498-9.
16. Panteghini M, Apple FS, Christenson RH, et al. Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. Clin Chem Lab Med 1999;37:687-93.
17. Panteghini M, Gerhardt W, Apple FS, et al . Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001;39:175-9. (Pubitemid 32318485)
18. Stefanini GG, Serruys PW, Silber S, et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimuseluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011;57:2221-32.
19. Jaffe AS, Apple FS, Lindahl B, et al. Why all the struggle about CK-MB and PCI? Eur Heart J 2012;33:1046-8.
20. Babu GG, Walker JM, Yellon DM, et al. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J 2011;32:396-403.
21. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6. (Pubitemid 34123427)
22. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642-7. (Pubitemid 32738516)
23. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 2009;54:477-86.
24. Novack V, Pencina M, Cohen DJ, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012;172:502-8.
25. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004;93:18-23. (Pubitemid 38022028)
26. Natarajan MK, Kreatsoulas C, Velianou JL, et al. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 2004;93:750-3. (Pubitemid 38338569)
27. Scirica BM, Morrow DA. Troponins in acute coronary syndromes. Prog Cardiovasc Dis 2004;47:177-88. (Pubitemid 40037317)
28. Twerenbold R, Jaffe A, Reichlin T, et al. High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J 2012;33:579-86.
29. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5. (Pubitemid 46648623)